Elgan Pharma Announces Positive Results from Its Phase III Study of ELGN-GI in Preterm Infants for Treatment of Intestinal Malabsorption

Elgan Pharma released the findings of its Phase III study on the safety and efficacy of an insulin formulation for the treatment of intestinal malabsorption in preterm infants, called ELGN-GI.